Toronto, Ontario–(Newsfile Corp. – October 28, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction , announced today the success of phase one of its new chemical entity (NCE) development program to strengthen Awakn’s pipeline for the treatment of a…


Previous articleCybin Announces Launch of EMBARK Psychedelic Facilitator Training Program
Next articleAddressing Abuse in Psychedelic Spaces